0G99 Stock Overview
A biopharmaceutical company, develops medicines to prevent blindness. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oxurion NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.00 |
| 52 Week High | €17.00 |
| 52 Week Low | €1.00 |
| Beta | 0.58 |
| 11 Month Change | 0% |
| 3 Month Change | 100.00% |
| 1 Year Change | -77.78% |
| 33 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0G99 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | 0.8% |
| 1Y | -77.8% | -20.1% | 6.6% |
Return vs Industry: 0G99 underperformed the UK Biotechs industry which returned -17.3% over the past year.
Return vs Market: 0G99 underperformed the UK Market which returned 7.5% over the past year.
Price Volatility
| 0G99 volatility | |
|---|---|
| 0G99 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0G99's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0G99's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 20 | Pascal Ghoson | www.oxurion.com |
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018.
Oxurion NV Fundamentals Summary
| 0G99 fundamental statistics | |
|---|---|
| Market cap | €400.21k |
| Earnings (TTM) | -€11.37m |
| Revenue (TTM) | €84.00k |
4.8x
P/S Ratio0.0x
P/E RatioIs 0G99 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0G99 income statement (TTM) | |
|---|---|
| Revenue | €84.00k |
| Cost of Revenue | €105.00k |
| Gross Profit | -€21.00k |
| Other Expenses | €11.35m |
| Earnings | -€11.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.51 |
| Gross Margin | -25.00% |
| Net Profit Margin | -13,539.29% |
| Debt/Equity Ratio | -78.8% |
How did 0G99 perform over the long term?
See historical performance and comparison